Asthma+me SMART: Development of an AI-supported clinical decision support system for children with moderate-to-severe asthma treated in specialist paediatric clinics.

Asthma me SMART：为在儿科专科诊所治疗的中重度哮喘儿童开发人工智能支持的临床决策支持系统。

• 批准号: 105181
• 金额: $ 49.35万
• 依托单位: ASEPTIKA LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2019
• 资助国家: 英国
• 起止时间: 2019 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=105181
• 关键词: Asthma+me; SMART; Development; AI; supported

"Asthma affects 1.1 million UK children costing more than £58m per annum. Aseptika's cloud-based technology supporting disease management (www.activ8rlives.com) is ready to be developed as a clinical healthcare management device. Our previous SBRI/Innovate UK projects shows that paediatric asthma patients, once referred to the specialist clinic, tend to remain within the clinic re-call system. Very large numbers of paediatric patients are therefore attending specialist clinics for short duration recall visits. Using our Asthma+me SMART system with our proprietary connected devices and artificial intelligence integrated system, we can support earlier discharge from the clinic while providing patient-centred management of asthma. The system, remotely linked to the specialist clinic and employing AI-based disease status monitoring and decision support, will significantly impact clinical care within the NHS.We will develop an Artificial Intelligence-based asthma monitoring system that will be embedded into our Asthma+me SMART phone App. The system will monitor patient asthma status and through monitoring the data being collected each day, will be able to identify when there is a risk of moving from well to less-well controlled situations and alert to asthma attacks. The App will provide a range of automated support to the patient and also send clinical disease status reports to the clinician identifying data of clinical interest for patient risk stratification.To achieve our objectives we will design, build and validate our AI system by collecting asthma patient data from the Sheffield Childrens' Hospital clinic. These data will be used to train our system to recognise patterns of well and poorly controlled asthma. The outcome of this project will be the Asthma+me SMART that will be ready for regulatory approvals.The Asthma+me SMART solution will be a highly innovative and interactive system that will allow enhanced disease management by the patient, family and clinician, increased remote self-management of asthma while providing comfort that the asthma clinic is aware of the patient disease status.Our Asthma+me SMART system will positively impact the NHS specialist clinic work flows by automating repetitive tasks, encouraging parents to undertake more of the workload, decrease the numbers of follow-up appointments, reduce unscheduled hospital admissions and A&E attendance.For children with moderate-to-severe asthma, this will reduce referral times. For the NHS, this will reduce service utilisation and costs.Social benefits are: reduction in lost school days for affected children, fewer days taken off from work by parents and associated travel costs of attending clinics."

“哮喘影响了110万英国儿童，每年花费超过5800万英镑。ASeptika的支持疾病管理的基于云的技术(www.acti8rlives.com)已经准备好作为临床保健管理设备开发。我们以前的SBRI/Innovate UK项目显示，儿科哮喘患者一旦转诊到专科诊所，往往会留在诊所重新呼叫系统中。因此，非常多的儿科病人在短期内前往专科诊所就诊。使用我们的哮喘+我智能系统以及我们专有的连接设备和人工智能集成系统，我们可以支持更早出院，同时提供以患者为中心的哮喘管理。该系统远程链接到专家诊所，并采用基于人工智能的疾病状态监测和决策支持，将对NHS内的临床护理产生重大影响。我们将开发一个基于人工智能的哮喘监测系统，该系统将嵌入我们的哮喘+Me智能手机应用程序。该系统将监测患者的哮喘状态，并通过监测每天收集的数据，将能够识别何时存在从良好控制状态转移到较差控制状态的风险，并对哮喘发作发出警报。该应用程序将为患者提供一系列自动化支持，并向临床医生发送临床疾病状态报告，以确定患者风险分层的临床兴趣数据。为了实现我们的目标，我们将通过收集谢菲尔德儿童医院诊所的哮喘患者数据来设计、构建和验证我们的人工智能系统。这些数据将被用来训练我们的系统，以识别控制良好和控制不良的哮喘模式。该项目的成果将是准备等待监管部门批准的哮喘+Me智能系统。哮喘+Me智能解决方案将是一个高度创新和互动的系统，将允许患者、家庭和临床医生增强疾病管理，增强哮喘的远程自我管理，同时提供哮喘诊所了解患者疾病状态的安慰。我们的哮喘+Me智能系统将通过自动化重复性任务、鼓励父母承担更多工作量、减少后续预约数量、减少非计划住院和急诊室就诊次数，对NHS专家诊所工作流程产生积极影响。对于患有中重度哮喘的儿童，这将减少转诊时间。对NHS来说，这将减少服务使用率和成本，社会效益包括：减少受影响儿童的上学天数，减少父母休假的天数，以及就诊的相关旅费。“